Tuesday January 16th 2018

Archive for September, 2017

Merck KGaA eyes up to 700 million euro Mavenclad sales in EU

Merck KGaA eyes up to 700 million euro Mavenclad sales in EU

FRANKFURT (Reuters) - Germany's Merck KGaA is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros ($823 million) in the European Union. (Source: Reuters: [Read More]

Merck KGaA eyes up to 700 million eur Mavenclad sales in EU

Merck KGaA eyes up to 700 million eur Mavenclad sales in EU

FRANKFURT (Reuters) - Germany's Merck KGaA is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros ($823 million) in the European Union. (Source: Reuters: [Read More]

Caffeine may not relieve movement symptoms for people with Parkinson’s

Caffeine may not relieve movement symptoms for people with Parkinson’s

Contrary to previous research, caffeine may not relieve movement symptoms for people with Parkinson's disease, according to a study published in the September 27, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. [Read More]

 Page 1 of 31  1  2  3  4  5 » ...  Last » 

Latest Topics

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

The FDA responded to a petition, saying that after reviewing the evidence, there is no basis for the claim that vitamin [Read More]

Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.

Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.

Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease of the central nervous system (CNS) with [Read More]

Researchers use novel PET tracer to assess myelin damage in mouse models of MS

Researchers use novel PET tracer to assess myelin damage in mouse models of MS

The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallmark of the [Read More]

MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe

MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe

The European Commission clears the anti-CD20 monoclonal antibody for adults with relapsing multiple sclerosis and early [Read More]

New PET radiotracer offers insight into multiple sclerosis

New PET radiotracer offers insight into multiple sclerosis

Combining PET scans with a novel radiotracer could help researchers track damage...Read more on AuntMinnie.comRelated [Read More]